Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline
04 oct. 2020 18h39 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
16 sept. 2020 21h30 HE
|
Sorrento Therapeutics, Inc.
Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with patient enrollment.The initial trial is expected to enroll rapidly...
Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2
19 août 2020 09h00 HE
|
Sorrento Therapeutics, Inc.
IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients.The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use...